SEARCH

SEARCH BY CITATION

References

  • 1
    Delfraissy, JF et al. Prise en charge thérapeutique des personnes infectées par le VIH. recommandations du groupe d'experts. France, Flammarion, 1999.
  • 2
    Smith, D, Whittaker, B, Crowe, S et al. Antiretroviral therapy for HIV infection: principles of use (standard of care guidelines). HIV/AIDS Clinical trials and treatments advisory committee booklet (October), 1997.
  • 3
    Carpenter, CCJ, Cooper, DA, Fischl, MA et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society–USA Panel. JAMA 2000; 283, 381 390.
  • 4
    Centers for Disease Control and Prevention. Report of the NIH Panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998; 47, 1 91.
  • 5
    Gazzard, B & Moyle, G. on behalf of the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352, 314 316.
  • 6
    Hurwitz, B. Legal and political considerations of clinical practice guidelines. BMJ 1999; 318, 661 664.
  • 7
    Pozniak, A. Surrogacy in HIV-1 clinical trials. Lancet 1998; 351, 536 537.
  • 8
    Fleming, TR & Demets, DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125, 605 613.
  • 9
    De Gruttola, V, Fleming, T, Lin, DY, Coombs, R. Perspective: validating surrogate markers – are we being naive? J Infect Dis 1997; 175, 237 246.
  • 1
    Babiker, A. for the Delta Co-ordinating Committee and Virology Group. Can HIV-1 RNA viral load be used as a surrogate for clinical endpoints in HIV disease? 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, Germany. (abstract 103)., 1997.
  • 11
    Mellors, JW, Munoz, A, Giorgi, JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126, 946 954.
  • 12
    Gazzard, B, Hill, A, Gartland, M. for the AVANTI Study Group. Different analyses give highly variable estimates of HIV-1 RNA undetectability and log10 reduction in clinical trials. AIDS 1998; 12, S36((Abstract) P77).
  • 13
    Raboud, JM, Montaner, JSG, Conway, B et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998; 12, 1619 1624.
  • 14
    Zhu, T, Mo, H, Wang, N et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261, 1179 1181.
  • 15
    Zhang, LQ, Mackenzie, P, Cleland, A et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993; 67, 3345 3356.
  • 16
    Markowitz, M, Vesanen, M, Tenner-Racz, K et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type-1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179, 527 537.
  • 17
    Zhang, L, Ramratnam, B, Tenner-Racz, K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340, 1605 1613.
  • 18
    Koup, RA, Safrit, JT, Cao, Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68, 4650 4655.
  • 19
    Borrow, P, Lewicki, H, Hahn, BH, Shaw, GM, Oldstone, MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68, 6103 6110.
  • 20
    Rosenberg, ES, Billingsley, JM, Caliendo, AM et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia [see comments]. Science 1997; 278, 1447 1450.
  • 21
    Walker, BD, Rosenberg, ES, Hay, CM, Basgoz, N, Yang, OO. Immune control of HIV-1 replication. Adv Exp Med Biol 1998; 452, 159 167.
  • 22
    Lisziewicz, J, Rosenberg, E, Lieberman, J et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340, 1683 1684.
  • 23
    Wong, JK, Hezareh, M, Gunthard, HF et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278, 1291 1295.
  • 24
    Finzi, D, Hermankova, M, Pierson, T et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278, 1295 1300.
  • 25
    Chun, T-W, Carruth, L, Finzi, D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387, 183 187.
  • 26
    Ho, DD. Toward HIV eradication or remission: the tasks ahead. Science 1998; 280, 1866 1867.
  • 27
    Pontesilli, O, Kerkhof-Garde, S, Notermans, DW et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180, 76 86.
  • 28
    Fischl, MA, Richman, DD, Hansen, N et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990; 112, 727 737.
  • 29
    Concorde Coordinating Committee. Concorde. MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343, 871 881.
  • 30
    Perelson, AS, Neumann, AU, Markowitz, M et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time . Science 1996; 271, 1582 1586.
  • 31
    Yu, G, Clendennin, NJ, Quart, B et al. Viral load levels during treatment with VIRACEPT combination treatment as predictor of response and guidance for treatment choice strategy. 12th World AIDS Conference, Geneva. (abstract 12300)., 1998.
  • 32
    Gulick, RM, Mellors, JW, Havlir, D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337, 734 739.
  • 33
    Green, S, Para, MF, Daly, PW et al. Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 infected patients with Rescriptor (DLV) + Retrovir (ZDV) + Epivir (3TC). 12th World AIDS Conference, Geneva. (abstract 129/12219)., 1998.
  • 34
    Fischl, M, Greenberg, S, Clumeck, N et al. Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral naive subjects. 12th World AIDS Conference, Geneva. (abstract 127/12230)., 1998.
  • 35
    Gisolf, EH, De Wolf, F, Van Wanzeele, F et al. Treatment of ritonavir (RTV) /saquinavir (SQV) versus RTV/SQV/stavudine (d4T) (the Prometheus study): preliminary results. 12th World AIDS Conference, Geneva. (abstract 12274)., 1998.
  • 36
    Tashima, K, Staszewski, S, Stryker, R et al. A phase III, multicenter, randomized, open-label study to comapre the antiretroviral activity and tolerability of efavirenz + indinavir, versus EFV + zidovudine + lamivudine, versus IDV + ZDV + 3TC at 48 weeks. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract LB-16)., 1999.
  • 37
    Farzadegan, H, Hoover, DR, Astemborski, J et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352, 1510 1514.
  • 38
    Katzenstein, DA, Hammer, SM, Hughes, MD et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200–500, CD4 cells per cubic millimeter. N Engl J Med 1996; 335, 1091 1098.
  • 39
    Bush, CE, Donovan, RM, Markowitz, N et al. Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. J Clin Microbiol 1996; 34, 970 972.
  • 40
    Moore, RD, Cheever, L, Keruly, JC, Chaisson, RE. Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet 1999; 353, 463 464.
  • 41
    Stein, DS, Korvick, JA, Vermund, SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review [see comments]. J Infect Dis 1992; 165, 352 363.
  • 42
    Autran, B, Carcelain, G, Li, T et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277, 112 116.
  • 43
    Brun-Vezinet, F et al. Virologic failure, resistance and plasma drug measurements in an induction maintenance therapy trial (ANRS 072 Trilege). International Conference on the Discovery and Clinical Development of Antiretroviral Therapies, St Thomas, US Virgin Islands. (abstract 15)., 1998.
  • 44
    Paterson, D, Swindells, S, Mohr, J et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract 92)., 1999.
  • 45
    Demasi, R, Tolson, J, Pham, S et al. Self-reported adherence to HAART and correlation with HIV RNA. initial results with the Patient Medication Adherence Questionnaire. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract 94)., 1999.
  • 46
    Woodward, J, Wareham, PS, Grohskopf, L, Madigan, D, Hooton, TM. Protease inhibitor adherence and HIV-1 RNA response. 12th World AIDS Conference, Geneva. (abstract 60363)., 1998.
  • 47
    Ferrando, SJ, Wall, TL, Batki, SL, Sorensen, JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse 1996; 22, 475 487.
  • 48
    Broers, B, Morabia, A, Hirschel, B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994; 154, 1121 1127.
  • 49
    Miller, L, Liu, H, Beck, K et al. Providers' estimates of adherence overestimate reports from Medication Event Monitoring System (MEMS) for patients on protease inhibitors (PIs). 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract 97)., 1999.
  • 50
    Anderson, W et al. Taking Heart? The impact of combination therapy on the lives of people with HIV (Phase 2). London, Sigma Research, 1999.
  • 51
    Arabe, J, Rubini, NPM, Rodrigues, ACA et al. Factors which influence adherence to the use of protease inhibitors. 12th World AIDS Conference, Geneva. (abstract 32404)., 1998.
  • 52
    Bachiller, P, Arrando, FR, Liceaga, G et al. Adherence to antiretroviral therapy in HIV-infected patients. 12th World AIDS Conference, Geneva. (abstract 32392)., 1998.
  • 53
    Gifford, AL, Shively, MJ, Bormann, JE et al. Self-reported adherence to combination antiretroviral medication (ARV) regimens in a community-based sample of HIV-infected adults. 12th World AIDS Conference, Geneva. (abstract 32338)., 1998.
  • 54
    Lorenzen, T, Stoehr, A, Weitner, L et al. Compliance with antiretroviral multidrug therapy in HIV-infected patients and reasons for non-compliance. 12th World AIDS Conference, Geneva. (abstract 32371)., 1998.
  • 55
    Nakashima, AK, Jones, JL, Burgess, DA, Ward, JW. Adherence to currently prescribed antiretroviral therapies: results from a multisite interview project. 12th World AIDS Conference, Geneva. (abstract 32326)., 1998.
  • 56
    Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269, 729 730.
  • 57
    Palella, FJ, Delaney, KM, Moorman, AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338, 853 860.
  • 58
    Hammer, SM, Squires, KM, Hughes, MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337, 725 733.
  • 59
    Cameron, DW, Heath-Chiozzi, M, Danner, S et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351, 543 549.
  • 60
    Haubrich, R, Lalezari, J, Follansbee, SE et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998; 3, 33 42.
  • 61
    Kirk, O, Katzenstein, TL, Gerstoft, J et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999; 13, F9 F16.
  • 62
    Moyle, G & on behalf of the Spice Study team. Study of protease inhibitor combination in Europe (Spice) ; saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV-infected individuals. 12th World AIDS Conference. Geneva. (abstract 12222)., 1998.
  • 63
    D'aquila, RT, Hughes, MD, Johnson, VA et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol, 241 Investigators. Ann Intern Med 1996; 124, 1019 1030.
  • 64
    Moyle, GJ, Baldwin, C, Dent, N et al. Management of protease inhibitor (PI) -associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. (abstract 2064)., 1999.
  • 65
    Montaner, JSG, Reiss, P, Cooper, D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. JAMA 1998; 279, 930 937.
  • 66
    Murphy, RL, Katlama, C, Johnson, V et al. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI) -sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. (abstract LB-22)., 1999.
  • 67
    Kaspar, R. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. (abstract I-64)., 1998.
  • 68
    Hawkins, D, Wood, R, Horban, A et al. Final 54-week analysis of a study comparing the safety and antiretroviral activity of dual nucleoside analogues plus placebo versus dual nucleoside analogues plus delavirdine (DLV) in an advanced, treatment-naive HIV-infected population. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon. (abstract 550)., 1999.
  • 69
    Hawkins, D, Wood, R, Horban, A et al. Final 54-week analysis of a study comparing the safety and antiretroviral activity of dual nucleoside analogues plus placebo versus dual nucleoside analogues plus delavirdine (DLV) in an advanced, nucleoside analogue-experienced HIV-infected population. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon. (abstract 552)., 1999.
  • 70
    Larder, BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36, 2664 2669.
  • 71
    Kaufmann, D, Pantaleo, G, Sudre, P, Telenti, A. for the Swiss HIV Cohort Study. CD4-cell counts in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351, 723 724.
  • 72
    Caesar Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349, 1413 1421.
  • 73
    Larder, BA, Kemp, SD, Harrigan, PR. Potential mechanism for sustained antiretroviral efficacy of AZT−3TC combination therapy. Science 1995; 269, 696 699.
  • 74
    Staszewski, S, Katlama, C, Herrer, T et al. Long-term, 72 week experience with a triple reverse transcriptase nucleoside therapy regimen containing abacavir (1592, ABC): a follow-up of protocol CNA2002. AIDS 1998; 12, S34((Abstract) 69).
  • 75
    Staszewski, S, Keiser, P, Gathe, J et al. Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naïve adults at 48 weeks (CNA3005). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. (abstract 505)., 1999.
  • 76
    Havlir, DV, Friedland, G, Pollard, R et al. Combination zidovudine and stavudine therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298). 5th Conference on retroviruses and Opportunistic Infections, Chicago. ((Abstract) 2)., 1998.
  • 77
    Brinkman, K, Ter Hofstede, HJ, Burger, DM et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [editorial]. AIDS 1998; 12, 1735 1744.
  • 78
    Fouty, B, Frerman, F, Reves, R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352, 291 292.
  • 79
    Lori, F, Malykh, A, Cara, A et al. Hydroxyurea as an inhibitor of human immunodeficiency virus Type-1 replication. Science 1994; 266, 801 805.
  • 80
    De Boer, RJ, Boucher, CAB, Perelson, AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998; 12, 1567 1570.
  • 81
    De Antoni, A, Foli, A, Lisziewicz, J, Lori, F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997; 176, 899 903.
  • 82
    Rossero, R, Mckinsey, D, Green, S et al. Open label combination therapy with stavudine, didanosine and hydroxyurea in nucleoside experienced HIV-1 infected patients. 5th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract 653)., 1998.
  • 83
    Margolis, D, Heredia, A, Gaywee, J et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999; 21, 362 370.
  • 84
    Petersen, A, Antunes, F, Arasteh, KN et al. A comparison of the long-term antiviral efficacy of bid and tid dosing of nelfinavir in combination with stavudine (d4T) and lamivudine (3TC) beyond 48 weeks. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, October. (abstract 205)., 1999.
  • 85
    Barry, MG, Merry, C, Lloyd, J et al. Variability in trough plasma saquinavir concentrations in HIV patients – a case for therapeutic drug monitoring [letter]. Br J Clin Pharmacol 1998; 45, 501 502.
  • 86
    Back, D, Eagling, V, Profit, L. Saquinavir absorption: role of P-glycoprotein. AIDS.; 12 (abstract P53)., 1998.
  • 87
    Fletcher, CV, Kakuda, TN, Anderson, PL et al. Viral dynamics of concentration-targeted (C) vs. standard-dose (S) therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September. (abstract 322)., 1999.
  • 88
    Havlir, DV, Marschener, IC, Hirsch, MS et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339, 1261 1268.
  • 89
    Ruiz, L, Van Lunzen, J, Arno, A et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13, F1 F8.
  • 90
    Taylor, S, Back, DJ, Workman, J et al. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 1999; 13, 859 860.
  • 91
    Danner, SA, Carr, A, Leonard, JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European–Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333, 1528 1533.
  • 92
    Di Perri, G, Del Bravo, P, Concia, E. HIV-protease inhibitors. N Engl J Med 1998; 339, 773 774.
  • 93
    Nelson, MR, Moyle, G, Newell, A. The incidence of hyperlipidaemia with protease inhibitors (PI). 38th Interscience Conference in Antimicrobial Agents and Chemotherapy, San Diego,1998.
  • 94
    Carr, A, Samaras, K, Chisholm, DJ, Cooper, DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 352, 1881 1883.
  • 95
    Carr, A, Samaras, K, Burton, S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12, F51 F58.
  • 96
    Henry, K, Melroe, H, Huebsch, J et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351, 1328.
  • 97
    Madge, S, Kinloch -d, E-Loes, S, Mercey, D, Johnson, MA, Weller, IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13, 735 737.
  • 98
    Dong, K, Flynn, MM, Dickinson, BP et al. Changes in body habitus in HIV+ women after initiation of protease inhibitor therapy. 12th World AIDS Conference, Geneva. (abstract 12373)., 1998.
  • 99
    Lo, J, Mulligan, K, Tai, V, Algren, H, Schambelen, M. ‘Buffalo hump’ in men with HIV-1 infection. Lancet 1998; 351, 867 870.
  • 100
    Veny, A, Bonjoch, A, Romeu, J et al. Cumulative risk for developing protease inhibitor-associated lipodystrophy (PI-AL) in HIV-infected patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. (abstract I-92)., 1998.
  • 101
    Miller, K, Jones, E, Yanovski, J et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351, 871 875.
  • 102
    Brinkman, K, Smeitink, JA, Romijn, JA, Reiss, P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354, 1112 1115.
  • 103
    Saint-Marc, T & Touraine, JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI) therapy. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract 672)., 1999.
  • 104
    Torres, R & Unger, K. The effect of recombinant human growth hormone on protease-inhibitor-associated fat maldistribution. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract 675)., 1999.
  • 105
    Ruiz, L, Bonjoch, A, Paredes, R et al. A multi-center, randomized, open-label comparative trial of the clinical benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract LB-14)., 1999.
  • 106
    Yee, TT, Amrolia, PJ, Lee, CA et al. Protease inhibitors and unusual bleeding in haemophiliacs. Haemophilia 1997; 3, 219 221.
  • 107
    Wilde, JT, Lee, CA, Collins, P et al. Increased bleeding associated with PI therapy in HIV-positive patients with bleeding disorders. Br J Haematol 1999; 107, 556 559.
  • 108
    Pilcher, CD, Miller, WC, Beatty, ZA, Eron, JJ. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS 1999; 13, 1337 1342.
  • 109
    Gulick, RM, Mellors, JW, Havlir, D et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection. JAMA 1998; 280, 35 41.
  • 110
    Goebel, F & the Avanti Study Group. Avanti, 2. A randomised, double-blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs. AZT/3TC/Indinavir in antiretroviral naive patients. 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg. (abstract 211)., 1997.
  • 111
    Riddler, S, Kahn, J, Hicks, C et al. Durable anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) [DMP 266–003, Cohort IV]. 12th World AIDS Conference, Geneva. (abstract 12359)., 1998.
  • 112
    Lorenzi, P, Opravil, M, Hirschel, B et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13, F17 F21.
  • 113
    Youle, M, Mocroft, A, Johnson, M et al. Surrogate marker responses to multidrug combination hydroxyurea, efavirenz, double protease inhibitors and analogues in protease inhibitor failures. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract 400)., 1999.
  • 114
    Deeks, SG, Hecht, FM, Swanson, M et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13, F35 F43.
  • 115
    Tebas, P, Patick, AK, Kane, EM et al. Virologic responses to a ritonavir – saquinavir-containing regimen in patients who had previously failed nelfinavir. Aids 1999; 13, F23 F28.
  • 116
    Eron, J, Falloon, J, Masur, H et al. Activity of Combination Abacavir/Amprenavir/Efavirenz Therapy in HIV-1 Infected Subjects Failing Their Current Protease Inhibitor Containing Regimen 1998; 12, S13((Abstract) OP52).
  • 117
    Workman, C, Mussen, R, Sullivan, J. Salvage therapy using six drugs in heavily pretreated patients. 5th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract 426)., 1998.
  • 118
    Garcia, F, Plana, M, Vidal, C et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. Aids 1999; 13, F79 F86.
  • 119
    Ledergerber, B, Egger, M, Opravil, M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353, 863 868.
  • 120
    Deeks, SG, Parkin, N, Petropoulos, CJ et al. Correlation of baseline phenotypic drug susceptibility with 16 week virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy. Antiviral Ther 1998; 3, 36((Abstract) 53).
  • 121
    Patick, A, Zhang, M, Hertogs, K et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Antiviral Ther 1998; 3, 39((Abstract) 57).
  • 122
    Harrigan, PR, Montaner, JS, Hogg, RS et al. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. Antiviral Ther 1998; 3, 38((Abstract) 55).
  • 123
    Zolopa, AR, Shafer, RW, Warford, A et al. Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Antiviral Ther 1998; 3, 37((Abstract) 54).
  • 124
    Baxter, JD, Mayers, DL, Wentworth, DN, Neaton, JD, Merigan, TC & the CPCRA, 046 Study Team. . A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract LB8)., 1999.
  • 125
    Durant, J, Clevenbergh, P, Halfon, P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353, 2195 2199.
  • 126
    Stuyver, L, Wyseur, A, Rombout, A et al. Line probe assay for rapid detection of drug-selected mutations in the Human Immunodeficiency Virus Type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997; 41, 284 291.
  • 127
    Arnold, C, Barlow, KL, Kaye, S et al. HIV type 1 sequence subtype G transmission from mother to infant: failure of variant sequence species to amplify in the Roche Amplicor Test. AIDS Res Hum Retroviruses 1995; 11, 999 1001.
  • 128
    Perrin, L. Transmission of drug-resistant HIV. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract S35)., 1999.
  • 129
    Little, S, Daar, E, Keiser, P et al. The spectrum and frequency of reduced antiretroviral drug susceptibility with primary HIV infection in the United States. 6th Conference on Retroviruses and Opportunistic Infections, Chicago. (abstract LB-10)., 1999.
  • 130
    Taylor, GP, Lyall, EGH, Mercey, D et al. British HIV Association Guidelines for Prescribing Antiretroviral Therapy in Pregnancy 1998. Sex Transm Inf 1999; 75, 90 97.
  • 131
    Expert Advisory Group on, AIDS. Guidelines on Post-Exposure Prophylaxis for Health Care Workers Occupationally Exposed to HIV. London, Department of Health, 1997.